Evaluation the Frequency of Resistance to Pyrazinamide Among Drug-Resistant Strains of Mycobacterium tuberculosis in Isfahan, Iran

AUTHORS

Bahram Nasr-Esfahani 1 , Sharareh Moghim 1 , Mahshid Salehi 2 , Masoud Keikha ORCID 3 , *

1 Department of Microbiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

2 Regional Tuberculosis Reference Laboratories in Isfahan, Isfahan, Iran

3 Department of Microbiology and Virology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

How to Cite: Nasr-Esfahani B, Moghim S, Salehi M, Keikha M. Evaluation the Frequency of Resistance to Pyrazinamide Among Drug-Resistant Strains of Mycobacterium tuberculosis in Isfahan, Iran, Arch Clin Infect Dis.2021 In Press(In Press): e101092. doi: 10.5812/archcid.101092.

ARTICLE INFORMATION

Archives of Clinical Infectious Diseases: In Press (In Press); e101092
Published Online: May 31, 2021
Article Type: Research Article
Received: January 20, 2020
Revised: May 05, 2021
Accepted: May 09, 2021
Crossmark
Crossmark
CHECKING
READ FULL TEXT

Abstract

Background: Pyrazinamide is one of the most important first line medications in treatment of tuberculosis and the alternative intake for MDR-TB and XDR-TB patients.

Objectives: The purpose of this study was evaluating the resistance to pyrazinamide in the isolates resistant to Mycobacterium tuberculosis drug for the required patients in the city of Isfahan.

Methods: In this study, the drug susceptibility test was performed with pyrazinamide using proportion method and PZA assay on 47 isolates resistant to mycobacterium tuberculosis. Then, the mutation of pncA and rpsA genes of the isolates resistant to pyrazinamide was evaluated by the sequencing method.

Results: According to the proposition method, 19 cases were resistant to pyrazinamide, 16 of whom had mutations in their pncA and rpsA genes; in this study, 5 new mutations were recorded and 3 isolates lacked mutations in the mentioned genes.

Conclusions: Pyrazinamide resistance is high in MDR-TB and INH mono-resistant isolates. Therefore, evaluating the susceptibility of pyrazinamide to patients with MDR-TB before initiation of treatment with pyrazinamide is considered essential.

Fulltext

© 2021, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
COMMENTS

LEAVE A COMMENT HERE: